72 reports of this reaction
1.5% of all METHYLENE BLUE reports
#11 most reported adverse reaction
BLOOD CREATINE PHOSPHOKINASE INCREASED is the #11 most commonly reported adverse reaction for METHYLENE BLUE, manufactured by American Regent, Inc.. There are 72 FDA adverse event reports linking METHYLENE BLUE to BLOOD CREATINE PHOSPHOKINASE INCREASED. This represents approximately 1.5% of all 4,684 adverse event reports for this drug.
Patients taking METHYLENE BLUE who experience blood creatine phosphokinase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD CREATINE PHOSPHOKINASE INCREASED is a less commonly reported adverse event for METHYLENE BLUE, but still significant enough to appear in the safety profile.
In addition to blood creatine phosphokinase increased, the following adverse reactions have been reported for METHYLENE BLUE:
The following drugs have also been linked to blood creatine phosphokinase increased in FDA adverse event reports:
BLOOD CREATINE PHOSPHOKINASE INCREASED has been reported as an adverse event in 72 FDA reports for METHYLENE BLUE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD CREATINE PHOSPHOKINASE INCREASED accounts for approximately 1.5% of all adverse event reports for METHYLENE BLUE, making it a notable side effect.
If you experience blood creatine phosphokinase increased while taking METHYLENE BLUE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.